“johnson-johnson” Archives

in
Entry Author Date Location
“Opioid Stacking” Concerns Lead FDA to Reject Avenue Therapeutics Drug 10/12/20 New York
In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug 10/08/20 National
Orphazyme Stock Sale Reaps $83M as Neimann-Pick Drug Review Begins 09/29/20 Europe
Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More 09/25/20 National
Tau-Targeting Alzheimer’s Drug from AC Immune, Roche Fails in Phase 2 09/23/20 Europe
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue 09/09/20 National
Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More 08/21/20 National
J&J Boosts Autoimmune Disease Drug Pipeline With $6.5B Momenta Buyout 08/19/20 New York
Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More 08/07/20 National
GlaxoSmithKline Multiple Myeloma Drug Earns FDA’s First Anti-BCMA Nod 08/06/20 National
IgGenix Grabs $10M to Advance Antibody Treatments for Allergies 08/05/20 San Francisco
Bio Roundup: Jazz Drug OK’d, Gilead’s Bet, Moderna Patent Decision & More 07/24/20 National
MeiraGTx, J&J See Phase 3 Test Ahead for Vision Loss Gene Therapy 07/17/20 New York
Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More 07/17/20 National
VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs 07/09/20 San Diego
Vor Nabs $110M to Spare Healthy Cells From Targeted Cancer Drugs 07/07/20 Boston
Moderna: Speed of COVID 19 Vaccine Hinges On Enrolling Right Patients 07/02/20 National
Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More 06/12/20 National
Moderna Finalizes Plan, Dose for Phase 3 Test of mRNA COVID Vaccine 06/11/20 Boston
AbbVie Commits $750M to Genmab Bispecific Antibody Cancer Drug Deal 06/10/20 National
Legend Biotech’s Upsized IPO Lands $424M for Multiple Myeloma Drug 06/05/20 New York
Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More 06/05/20 National
Chinook, Aduro Merger Plan Sets Up New Kidney Disease-Focused Biotech 06/02/20 Seattle
Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq 05/22/20 National
From Overseas, Legend Biotech and Calliditas Therapeutics Eye the Nasdaq 05/15/20 New York
BCMA Delay: FDA Refuses Review of Bristol Drug, Asks for More Info 05/13/20 New York
Adicet Aims to Advance CAR-T Therapies in Reverse Merger with resTORbio 04/29/20 Boston
Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19) 04/22/20 National
FDA Approves Incyte Drug, First Ever for Rare Bile Duct Cancer 04/20/20 National
COVID-19 Vax Efforts Aim to Balance Speed, Efficacy in Race to Market 04/17/20 National
Page 1 of 18 next page »